{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T16:28:35Z","timestamp":1794068915851,"version":"4.8.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,1,7]],"date-time":"2019-01-07T00:00:00Z","timestamp":1546819200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004332","name":"Seoul National University Hospital","doi-asserted-by":"crossref","award":["03-2015-0380"],"award-info":[{"award-number":["03-2015-0380"]}],"id":[{"id":"10.13039\/501100004332","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12885-018-5214-8","type":"journal-article","created":{"date-parts":[[2019,1,7]],"date-time":"2019-01-07T06:04:46Z","timestamp":1546841086000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":69,"title":["Differences in tumor microenvironments between primary lung tumors and brain metastases in lung cancer patients: therapeutic implications for immune checkpoint inhibitors"],"prefix":"10.1186","volume":"19","author":[{"given":"Ryul","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhumsuk","family":"Keam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sehui","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miso","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Wook","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu Jung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae Min","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoon Kyung","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Wan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doo Hyun","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong Seok","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dae Seog","family":"Heo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,7]]},"reference":[{"issue":"1","key":"5214_CR1","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1007\/s11912-011-0203-y","volume":"14","author":"L Nayak","year":"2012","unstructured":"Nayak L, Lee EQ, Wen PY. Epidemiology of brain metastases. Curr Oncol Rep. 2012;14(1):48\u201354.","journal-title":"Curr Oncol Rep"},{"issue":"9","key":"5214_CR2","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1200\/JCO.1988.6.9.1474","volume":"6","author":"JB Sorensen","year":"1988","unstructured":"Sorensen JB, Hansen HH, Hansen M, Dombernowsky P. Brain metastases in adenocarcinoma of the lung: frequency, risk groups, and prognosis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1988;6(9):1474\u201380.","journal-title":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology"},{"key":"5214_CR3","first-page":"241","volume":"54","author":"D Mathieu","year":"2007","unstructured":"Mathieu D, Kondziolka D, Cooper PB, Flickinger JC, Niranjan A, Agarwala S, Kirkwood J, Lunsford LD. Gamma knife radiosurgery for malignant melanoma brain metastases. Clin Neurosurg. 2007;54:241\u20137.","journal-title":"Clin Neurosurg"},{"issue":"1","key":"5214_CR4","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s11060-014-1359-8","volume":"117","author":"A Alomari","year":"2014","unstructured":"Alomari A, Rauch PJ, Orsaria M, Minja FJ, Chiang VL, Vortmeyer AO. Radiologic and histologic consequences of radiosurgery for brain tumors. J Neuro-Oncol. 2014;117(1):33\u201342.","journal-title":"J Neuro-Oncol"},{"key":"5214_CR5","doi-asserted-by":"crossref","unstructured":"Greene-Schloesser D, Robbins ME: Radiation-induced cognitive impairment--from bench to bedside. Neuro-oncology 2012, 14 Suppl 4:iv37\u2013iv44.","DOI":"10.1093\/neuonc\/nos196"},{"issue":"1","key":"5214_CR6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1200\/JCO.2012.46.0410","volume":"31","author":"AJ Khan","year":"2013","unstructured":"Khan AJ, Dicker AP. On the merits and limitations of whole-brain radiation therapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013;31(1):11\u20133.","journal-title":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology"},{"issue":"1","key":"5214_CR7","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1002\/cncr.23526","volume":"113","author":"DH Lee","year":"2008","unstructured":"Lee DH, Han JY, Kim HT, Yoon SJ, Pyo HR, Cho KH, Shin SH, Yoo H, Lee SH, Lee JS. Primary chemotherapy for newly diagnosed nonsmall cell lung cancer patients with synchronous brain metastases compared with whole-brain radiotherapy administered first : result of a randomized pilot study. Cancer. 2008;113(1):143\u20139.","journal-title":"Cancer"},{"issue":"4","key":"5214_CR8","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s11864-014-0307-3","volume":"15","author":"A Attia","year":"2014","unstructured":"Attia A, Page BR, Lesser GJ, Chan M. Treatment of radiation-induced cognitive decline. Curr Treat Options in Oncol. 2014;15(4):539\u201350.","journal-title":"Curr Treat Options in Oncol"},{"key":"5214_CR9","doi-asserted-by":"crossref","unstructured":"Peters S, Adjei AA, Gridelli C, Reck M, Kerr K, Felip E: Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of oncology : official journal of the European Society for Medical Oncology 2012, 23 Suppl 7:vii56\u2013vii64.","DOI":"10.1093\/annonc\/mds226"},{"issue":"8","key":"5214_CR10","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/nm730","volume":"8","author":"H Dong","year":"2002","unstructured":"Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8(8):793\u2013800.","journal-title":"Nat Med"},{"issue":"7","key":"5214_CR11","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","volume":"192","author":"GJ Freeman","year":"2000","unstructured":"Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne MC, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192(7):1027\u201334.","journal-title":"J Exp Med"},{"issue":"25","key":"5214_CR12","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1056\/NEJMoa1613493","volume":"376","author":"DP Carbone","year":"2017","unstructured":"Carbone DP, Reck M, Paz-Ares L, Creelan B, Horn L, Steins M, Felip E, van den Heuvel MM, Ciuleanu TE, Badin F, et al. First-line Nivolumab in stage IV or recurrent non-small-cell lung Cancer. N Engl J Med. 2017;376(25):2415\u201326.","journal-title":"N Engl J Med"},{"issue":"17","key":"5214_CR13","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","volume":"373","author":"H Borghaei","year":"2015","unstructured":"Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung Cancer. N Engl J Med. 2015;373(17):1627\u201339.","journal-title":"N Engl J Med"},{"issue":"2","key":"5214_CR14","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa1504627","volume":"373","author":"J Brahmer","year":"2015","unstructured":"Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung Cancer. N Engl J Med. 2015;373(2):123\u201335.","journal-title":"N Engl J Med"},{"issue":"21","key":"5214_CR15","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","volume":"372","author":"EB Garon","year":"2015","unstructured":"Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018\u201328.","journal-title":"N Engl J Med"},{"issue":"4","key":"5214_CR16","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320\u201330.","journal-title":"N Engl J Med"},{"issue":"26","key":"5214_CR17","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med. 2015;372(26):2521\u201332.","journal-title":"N Engl J Med"},{"issue":"6","key":"5214_CR18","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s11912-017-0596-3","volume":"19","author":"AC Tan","year":"2017","unstructured":"Tan AC, Heimberger AB, Menzies AM, Pavlakis N, Khasraw M. Immune checkpoint inhibitors for brain metastases. Curr Oncol Rep. 2017;19(6):38.","journal-title":"Curr Oncol Rep"},{"issue":"7","key":"5214_CR19","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/S1470-2045(16)30053-5","volume":"17","author":"SB Goldberg","year":"2016","unstructured":"Goldberg SB, Gettinger SN, Mahajan A, Chiang AC, Herbst RS, Sznol M, Tsiouris AJ, Cohen J, Vortmeyer A, Jilaveanu L, et al. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. The Lancet Oncology. 2016;17(7):976\u201383.","journal-title":"The Lancet Oncology"},{"issue":"5","key":"5214_CR20","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1470-2045(12)70090-6","volume":"13","author":"K Margolin","year":"2012","unstructured":"Margolin K, Ernstoff MS, Hamid O, Lawrence D, McDermott D, Puzanov I, Wolchok JD, Clark JI, Sznol M, Logan TF, et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. The Lancet Oncology. 2012;13(5):459\u201365.","journal-title":"The Lancet Oncology"},{"issue":"11","key":"5214_CR21","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1038\/nm.3394","volume":"19","author":"DF Quail","year":"2013","unstructured":"Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013;19(11):1423\u201337.","journal-title":"Nat Med"},{"issue":"10","key":"5214_CR22","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1093\/annonc\/mdw289","volume":"27","author":"AS Mansfield","year":"2016","unstructured":"Mansfield AS, Aubry MC, Moser JC, Harrington SM, Dronca RS, Park SS, Dong H. Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2016;27(10):1953\u20138.","journal-title":"Annals of oncology : official journal of the European Society for Medical Oncology"},{"issue":"3","key":"5214_CR23","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.ccell.2017.02.009","volume":"31","author":"DF Quail","year":"2017","unstructured":"Quail DF, Joyce JA. The microenvironmental landscape of brain tumors. Cancer Cell. 2017;31(3):326\u201341.","journal-title":"Cancer Cell"},{"key":"5214_CR24","doi-asserted-by":"crossref","unstructured":"Qian JM, Mahajan A, Yu JB, Tsiouris AJ, Goldberg SB, Kluger HM, Chiang VLS. Comparing available criteria for measuring brain metastasis response to immunotherapy. J Neuro-Oncol. 2017:1\u20137.","DOI":"10.1007\/s11060-017-2398-8"},{"issue":"9","key":"5214_CR25","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1038\/modpathol.2015.63","volume":"28","author":"J Koh","year":"2015","unstructured":"Koh J, Go H, Keam B, Kim MY, Nam SJ, Kim TM, Lee SH, Min HS, Kim YT, Kim DW, et al. Clinicopathologic analysis of programmed cell death-1 and programmed cell death-ligand 1 and 2 expressions in pulmonary adenocarcinoma: comparison with histology and driver oncogenic alteration status. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2015;28(9):1154\u201366.","journal-title":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc"},{"issue":"12","key":"5214_CR26","doi-asserted-by":"publisher","first-page":"8448","DOI":"10.4049\/jimmunol.177.12.8448","volume":"177","author":"RM Prins","year":"2006","unstructured":"Prins RM, Vo DD, Khan-Farooqi H, Yang MY, Soto H, Economou JS, Liau LM, Ribas A. NK and CD4 cells collaborate to protect against melanoma tumor formation in the brain. Journal of immunology. 2006;177(12):8448\u201355.","journal-title":"Journal of immunology"},{"key":"5214_CR27","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1111\/j.1600-065X.2006.00441.x","volume":"213","author":"MJ Carson","year":"2006","unstructured":"Carson MJ, Doose JM, Melchior B, Schmid CD, Ploix CC. CNS immune privilege: hiding in plain sight. Immunol Rev. 2006;213:48\u201365.","journal-title":"Immunol Rev"},{"key":"5214_CR28","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3389\/fonc.2016.00049","volume":"6","author":"JV Cohen","year":"2016","unstructured":"Cohen JV, Kluger HM. Systemic immunotherapy for the treatment of brain metastases. Front Oncol. 2016;6:49.","journal-title":"Front Oncol"},{"issue":"17","key":"5214_CR29","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1200\/JCO.2014.56.2736","volume":"33","author":"D Schadendorf","year":"2015","unstructured":"Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, Patt D, Chen TT, Berman DM, Wolchok JD. Pooled analysis of Long-term survival data from phase II and phase III trials of Ipilimumab in Unresectable or metastatic melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015;33(17):1889\u201394.","journal-title":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology"},{"key":"5214_CR30","first-page":"736","volume":"28","author":"SH Yoo MK","year":"2017","unstructured":"Yoo MK SH, Keam B, Kim TM, Kim D, Heo DS. Generalization and representativeness of phase III immune checkpoint inhibitor trials in NSCLC. Ann Oncol. 2017;28:736\u201344.","journal-title":"Ann Oncol"},{"key":"5214_CR31","doi-asserted-by":"crossref","unstructured":"Berghoff AS, Inan C, Ricken G, Widhalm G, Dieckmann K, Birner P, Oberndorfer F, Dome B, Bartsch R, Zielinski C et al: 1324PTUMOR-INFILTRATING LYMPHOCYTES (TILS) AND PD-L1 EXPRESSION IN NON- SMALL CELL LUNG CANCER BRAIN METASTASES (BM) AND MATCHED PRIMARY TUMORS (PT). Annals of Oncology 2014, 25(suppl_4):iv465-iv466.","DOI":"10.1093\/annonc\/mdu349.103"},{"issue":"38","key":"5214_CR32","doi-asserted-by":"publisher","first-page":"40836","DOI":"10.18632\/oncotarget.5696","volume":"6","author":"PN Harter","year":"2015","unstructured":"Harter PN, Bernatz S, Scholz A, Zeiner PS, Zinke J, Kiyose M, Blasel S, Beschorner R, Senft C, Bender B, et al. Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1\/PD-L1 immune checkpoints in human brain metastases. Oncotarget. 2015;6(38):40836\u201349.","journal-title":"Oncotarget"},{"issue":"8","key":"5214_CR33","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1093\/neuonc\/now309","volume":"19","author":"V Teglasi","year":"2017","unstructured":"Teglasi V, Reiniger L, Fabian K, Pipek O, Csala I, Bago AG, Varallyai P, Vizkeleti L, Rojko L, Timar J, et al. Evaluating the significance of density, localization, and PD-1\/PD-L1 immunopositivity of mononuclear cells in the clinical course of lung adenocarcinoma patients with brain metastasis. Neuro-Oncology. 2017;19(8):1058\u201367.","journal-title":"Neuro-Oncology"},{"issue":"13","key":"5214_CR34","doi-asserted-by":"publisher","first-page":"3052","DOI":"10.1158\/1078-0432.CCR-14-3073","volume":"21","author":"HM Kluger","year":"2015","unstructured":"Kluger HM, Zito CR, Barr ML, Baine MK, Chiang VL, Sznol M, Rimm DL, Chen L, Jilaveanu LB. Characterization of PD-L1 expression and associated T-cell infiltrates in metastatic melanoma samples from variable anatomic sites. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015;21(13):3052\u201360.","journal-title":"Clinical cancer research : an official journal of the American Association for Cancer Research"},{"key":"5214_CR35","doi-asserted-by":"crossref","unstructured":"Kerr KM, Nicolson MC. Non-small cell lung Cancer, PD-L1, and the pathologist. Arch Pathol Lab Med. 2016;140(3):249\u201354.","DOI":"10.5858\/arpa.2015-0303-SA"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-5214-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-018-5214-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-5214-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T20:43:41Z","timestamp":1662756221000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-018-5214-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,7]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["5214"],"URL":"https:\/\/doi.org\/10.1186\/s12885-018-5214-8","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,7]]},"assertion":[{"value":"23 November 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the SNUH Institutional Review Board (IRB approval number: H-1702-158-836) and was conducted in accordance with Declaration of Helsinki provisions. Written informed consent to participate in the study was obtained from each patient at admission.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"19"}}